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Abstract
The rapid evolution of Human Immunodeficiency Virus (HIV-1) allows studies of ongoing host–pathogen interactions. One
key selective host factor is APOBEC3G (hA3G) that can cause extensive and inactivating Guanosine-to-Adenosine (G-to-A)
mutation on HIV plus-strand DNA (termed hypermutation). HIV can inhibit this innate anti-viral defense through binding of
the viral protein Vif to hA3G, but binding efficiency varies and hypermutation frequencies fluctuate in patients. A pivotal
question is whether hA3G-induced G-to-A mutation is always lethal to the virus or if it may occur at sub-lethal frequencies
that could increase viral diversification. We show in vitro that limiting-levels of hA3G-activity (i.e. when only a single hA3G-
unit is likely to act on HIV) produce hypermutation frequencies similar to those in patients and demonstrate in silico that
potentially non-lethal G-to-A mutation rates are ,10-fold lower than the lowest observed hypermutation levels in vitro and
in vivo. Our results suggest that even a single incorporated hA3G-unit is likely to cause extensive and inactivating levels of
HIV hypermutation and that hypermutation therefore is typically a discrete ‘‘all or nothing’’ phenomenon. Thus, therapeutic
measures that inhibit the interaction between Vif and hA3G will likely not increase virus diversification but expand the
fraction of hypermutated proviruses within the infected host.
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Introduction
The HIV-1 population within an infected individual is
characterized by extensive viral variation and continuous
adaptation to its host. Such rapid evolution is the result of a
combination of several factors: a large viral population, high
replication and mutation rates, recombination, and various intra-
host selective pressures [1]. The high mutation rate is associated
with the inherent infidelity of HIV reverse transcriptase (RT) and
RNA polymerase II (RNA pol II) [1] and has also been proposed
to be partly caused by cellular cytidine deaminases such as hA3G,
which can cause Guanosine-to-Adenosine (G-to-A) mutations on
HIV plus-strand DNA [2–7]. Several observations appear to
provide support for this hypothesis as lentiviral genomes are
adenine rich [8,9] and G-to-A is the most frequent nucleotide
mutation observed during HIV-1 replication both in vitro [10,11]
and in vivo in both acute [12] and chronic infection [13].
In infected cells, hA3G can become incorporated into nascent
virions as large, enzymatically inactive, ribonucleoprotein com-
plexes termed ‘Intra-Virion A3G Complexes’ (IVAC) [14]. When
a virion subsequently infects another cell, IVACs become active
through the activity of viral RNaseH during reverse transcription
[14] and hA3G restricts HIV replication through a combination of
mutagenesis (or editing) [5,15] and possibly non-editing activities
[16]. Editing is easily recognized because it results in extensive
Cytidine-to-Uridine (C-to-U) deamination of single-stranded
minus-strand DNA during reverse transcription [5,17,18]. The
mutations appear as plus-strand G-to-A changes and hA3-induced
mutations are usually reported as such and termed hypermutation
[19] as G-to-A transitions far exceed all other mutations. As the
preferred target is TGG (encoding Tryptophan when in frame),
many G-to-A mutations will produce stop-codons, TAG, resulting
in viral inactivation [17,20].
The HIV accessory protein Vif can circumvent the protective
role of hA3G, and other hA3 deaminases, by targeting them for
proteasomal degradation and thereby preventing their incorpora-
tion into virions [21]. However, as various frequencies of
hypermutated sequences are observed in HIV DNA from infected
patients, the efficiency of these Vif-hA3 interactions must vary
between them [4,22–24].
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hypermutation frequency. First, editing could act to increase viral
diversification, with possible advantages to the virus in a
fluctuating fitness environment, but to do so, hA3G would have
to induce mutations at a low, sub-lethal level. In such a situation,
selection would act on Vif to moderate the number of hA3G
molecules incorporated into virions. Alternatively, inefficient Vif-
hA3G interactions could be the by-product of other hitherto
undefined selective pressures and the resulting hypermutation
considered a viral fitness cost, acting at the level of the viral
population.
Here, we investigate the fundamental question of whether
hA3G-induced G-to-A mutation is always lethal to the virus or if it
may occur at sub-lethal frequencies.
Results
hA3G levels and mutation rates in vitro and in vivo
To examine whether limiting-levels of hA3G activity could
result in sub-lethal mutation rates in HIV infections, we designed
an in vitro hA3G titration and sequencing experiment (Table 1).
Briefly, we made Vesicular Stomatitis Virus G protein (VSV-G)
pseudotyped Dvif-HIV(IIIB) virions, which incorporated variable
amounts of editing wild-type hA3G (wt-hA3G). The total hA3G
concentration was kept constant using the E259Q non-editing
hA3G mutant (E259Q-hA3G) [25]. These viruses were used to
infect TZM-bl cells (a HeLa cell line expressing HIV coreceptors
and a lacZ reporter gene under the control of an HIV LTR) in a
single-cycle infection assay from which DNA was extracted and
provirus amplified using limiting-dilution nested-PCR.
We examined total hA3G expression in both producer cell
lysates (Figure 1A) and purified virions (Figure 1B) for each
titration to test that transfections of both editing and non-editing
hA3G were equally efficient. Viruses with hA3G (wt- or E259Q-
hA3G) displayed large reductions in infectivity compared to virus
generated without hA3G, and the presence of increasing
concentrations of wt-hA3G conferred relatively greater losses of
infectivity, in line with previous studies (Figure 1C) [26].
We amplified and sequenced 8–20 env-to-39LTR fragments
(2.1 kb) from each hA3G titration. As the sequence of the parental
HIV(IIIB) virus is known (Figure S1), and the infections in our
experiments restricted to a single replication cycle, we could
readily identify all mutations induced by hA3G using HYPER-
MUT (www.hiv.lanl.gov). We found that 33/87 sequences had no
plus-strand G-to-A mutations while 48/87 were hypermutated
carrying greater than 4% GG-to-AG mutations (Figure 1D, Table
S1). In the remaining six sequences, a single G-to-A change was
found in either non-hA3G (5/6) or rare (1/6) hA3G contexts (as
defined in [20]), suggesting that RT/RNA pol II or PCR-related
errors may have been responsible. Of the hypermutated
sequences, all but one (47/48) carried stop codons, and as the
sequenced region corresponds to only ,20% of the protein-coding
genome, stop-codons likely exist in the rest of the genome.
Hypermutation levels in the lower three wt-hA3G titrations were
significantly lower than those in the higher titrations (p,0.0001,
unpaired t-test) (Figure 1D).
To evaluate whether these in vitro hypermutation rates were
representative of those occurring in vivo, we estimated the mutation
levels of 39 near-full length hypermutated patient-derived
proviruses (www.hiv.lanl.gov). As the parental viral sequences
were unknown, we made optimized reference sequences as in [20].
Briefly, reference sequences were estimated as the consensus of
closely related sequences identified by NJ phylogenetic tree
analysis of HIV subtype alignments in which potential hA3-type
hypermutation sites were ‘repaired’ (i.e. all AG and AA sites were
changed to NG and NA, respectively, if a GG or a GA was also
present at the same position in the alignment). We found that the
hypermutation levels observed in vivo were similar to those
observed in vitro (Figure 1D). Due to the lack of original patient-
derived non-hypermutated reference sequences, we were unable to
distinguish whether GG-to-AG mutation levels at ,5% of all GG
targets in these sequences were caused by hA3G or RT/RNA pol
II; however, an abundance of sequences with such low
hypermutation levels would imply a bimodal distribution of
mutation levels in natural infections, which would be inconsistent
with the in vitro data.
One editing-hA3G unit is likely to cause extensive
hypermutation
For hA3G editing to contribute to viral adaptation, the induced
mutations would need to occur at low, sub-lethal levels. This is
most likely to happen if just a single editing hA3G-unit is
incorporated into the virion. As hA3G may undergo RNA-
dependent oligomerization during virion assembly, the term
hA3G-unit is used here to refer to the active hA3G deaminase
[27]. We cannot know for certain whether the hypermutants we
observed in vitro did result from the incorporation of a single
editing unit, but conditional on assumptions about the incorpo-
ration process, we can estimate the probability that this was so.
We examined the maximum number of hA3G units that could
reside in a virion by considering the proportion of sequences
carrying hypermutation at each titration to derive a maximum
likelihood estimate (MLE) of the number of editing hA3G-units
per virion (Figure 1E, Figure S1). As the estimate depends on
hypermutation being observed, only the number of incorporated
hA3G-units with editing activity is estimated.
Our analysis assumed (i) that there is a finite number of
positions in a virion that can be occupied by hA3G-editing units
[28]; (ii) that the efficiency of transfection, protein expression, and
virion incorporation is the same for editing and non-editing hA3G
(as supported by Figure 1A and [28]; (iii) that there was sufficient
hA3G present in each titration for all positions to be occupied by
either editing or non-editing hA3G (as supported by the 100%
detection rate when 100% wild-type hA3G was present (Table S1)
(iv) that hA3G editing, when it had occurred in a sampled
Author Summary
Human cells have conserved antiviral defense systems,
which protect against a range of viruses. A key component
of this innate, intra-cellular defense is APOBEC3G (hA3G),
which can cause extensive and inactivating G-to-A
mutations (termed hypermutation) in viral DNA. To
circumvent this, human immunodeficiency virus type-1
(HIV-1) encodes a protein, Vif, which can bind hA3 and
prevent its antiviral effects. Vif is however, not always fully
efficient, and many HIV-1 infected patients harbor
hypermutated sequences. A key question is whether
hA3G also might generate sub-lethal levels of G-to-A
mutations, which could increase viral evolution, possibly
accelerating disease progression. If this were to occur,
drugs and vaccine-induced CTL-responses targeting Vif
might have counterproductive effects. We show through
in vitro, in vivo, and in silico analyses that it is unlikely that
hA3G-activity can enhance virus evolution. Thus, measures
that inhibit the interaction between Vif and APOBEC3G are
likely to only increase the fraction of hypermutated,
inactivated HIV sequences in the infected host.
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tion of uracil-containing edited viral DNA by cellular uracil DNA
glycosidases such as UNG2 and/or SMUG1 was insignificant
[3,29–31]. Under these assumptions, the probability that an
observed hypermutant resulted from a single wild-type hA3G unit
is approximately 12(k21)r/2, where k is the maximum possible
number of hA3G units that can be incorporated into a single
virion, and r is the proportion of hA3G present that was wild-type
when the hypermutant was generated (see Materials and Methods
for full details and Table 2).
The probability that we have observed the minimal level of
hA3G-induced hypermutation therefore depends on the number
of available positions, denoted k. Using assumptions (i)–(v) listed
above, we were able to derive a maximum likelihood estimator of k
that could be applied to the results of our titration experiments (see
Materials and Methods and Figure 1E). In this way, we estimated
that a virion could accommodate k=13 editing hA3G-units (95%
CI: 6–26 units) – an estimate that was robust to the removal of
each titration condition in turn (Figure 1E, Figure 2). This estimate
was similar to a previous biochemical estimate of 7+/24
molecules [28].
This estimate implies that in our transfection condition 2, in
which 1% of the hA3G was wild-type (r=0.01), an expected
12(1321)0.01/2=94% of hypermutants are predicted to have
resulted from the incorporation of a single virion. This figure rises
to 97% if we take the previous biochemical estimates of k (k=7
molecules; [28]), and remains as high as 87.5% if we take our
upper confidence interval (k=26).
Based on this analysis, it follows that our lower editing hA3G
titrations (with low r values) are highly likely to have recorded
hypermutation occurring at the lowest possible level. To further
assess the effects of hypermutation occuring in this way, and to
ensure that the hypermutation levels were not specific to the env-
39LTR region, we analyzed several near-full length proviral
sequences from these lower editing hA3G titrations (Figure 3). In
each case, 9–18% of all GG-motifs were mutated to AG, with
mutation occurring either side of each polypyrine tract, suggesting
that single editing hA3G-units can be active throughout the
genome. It has been hypothesized that editing rates are highest in
the regions most distal to the polypurine tracts, which are exposed
as a single-stranded DNA substrate for the longest times forming a
‘‘twin gradient’’ of mutational burden across the genome
[17,32,33]. Our previous study of in vitro and in vivo hypermutated
sequences demonstrated that reduced levels of editing immediately
downstream of the polypurine tracts were a common feature of
hA3G editing although hypermutation gradients were not always
evident [20], in agreement with the single editing hA3G-unit data
in Figure 3.
Transient transfections of hA3G in vitro have shown hA3G
incorporation into IVACs, but have also demonstrated that
overexpressed hA3G may become packaged external to the virion
core [14]. However, as only IVAC-associated hA3G has been
suggested to edit nascent viral DNA [14], our estimate (based on
the proportion of edited sequences) would be expected to just
reflect the number of IVAC-incorporated hA3G molecules,
regardless of potential hA3G overexpression. In the case non-
IVAC associated hA3G contributed to editing in this experiment,
even fewer hA3G-units would likely be incorporated in natural
infection, underscoring that extensive hypermutation can be
induced by a single or very few hA3G units.
Together, these results suggest that even a single incorporated
hA3G-unit is likely to cause extensive and inactivating levels of
HIV hypermutation, and that therefore, hypermutation is typically
a discrete ‘‘all or nothing’’ phenomenon.
In silico estimation of beneficial hA3G mutation rates
If hA3G-induced G-to-A mutations were to increase viral
diversification [2–7], they would have to be generated at a low,
sub-lethal level (Figure 4A). To determine how low this level
should be to permit neutral or potentially beneficial mutations
while avoiding lethal mutations (i.e. stop codons), we determined
hA3G tetranucleotide target preferences [20] and simulated
editing in silico (Figure 4B, 4C). A previous simulation study [34]
assumed, in effect, that hA3G induced a single mutation per round
of replication but this is in conflict with functional studies
demonstrating that hA3G moves along its single stranded DNA
template while inducing multiple mutations [35]. Accordingly, we
simulated here the effects of increasing hA3G-mediated mutation
rates on individual viruses.
We assumed that all stop codons within HIV genes would result
in non-functional virus and used the HIV(IIIB) open reading
frames (Figure S1 and Figure 4) to estimate the rate at which a
lethal mutation was induced in 50% of viral offspring (lethal
mutation 50% - LM50) using three different nucleotide targets: G-
to-A, GG-to-AG, and predefined hA3G-specific nGGn-to-nAGn
tetranucleotide contexts [20].
Table 1. hA3G titration transfection conditions.
Transfection
condition VH17 (mg) wt- hA3G (mg) E259Q-hA3G (mg) Total hA3G (mg) pCMV4HA (mg) VSV-G (mg)
1 301 1– 0 . 1 5
2 3 0.01 0.99 1 – 0.15
3 3 0.033 0.967 1 – 0.15
4 3 0.1 0.9 1 – 0.15
5 3 0.33 0.67 1 – 0.15
6 310 1– 0 . 1 5
7 300 01 0 . 1 5
VH17=Dvif HIV-1(IIIB) proviral construct.
wt-hA3G=wild-type editing hA3G construct.
E259Q-hA3G=E259Q non-editing mutant hA3G construct.
pCMV4HA=Empty vector.
VSV-G=Vesicular Stomatitis Virus-G envelope construct.
doi:10.1371/journal.pgen.1002550.t001
APOBEC3G, Hypermutation, and HIV Evolution
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target specificity. Considering all G-to-A targets (assuming that
hA3G recognized all Gn dinucleotide targets equally) an average
of 9 targets would have to be mutated to give a 50% chance of at
least one lethal mutation. However, if hA3G specificity was
considered using its preferred dinucleotide GG, only 3.8 out of 667
GG targets would need to be mutated to yield a 50% chance of at
least one lethal mutation. Furthermore, if specific hA3G
tetranucleotide target preferences (nGGn-to-nAGn) [20] were used
in the simulations, we estimate an LM50 of only 2.5 mutations,
implying that the innate anti-viral hA3G protein generate stop
codons very efficiently (Figure 4B). At an nGGn-to-nAGn rate of
Figure 1. hA3G-induced mutation frequency in vitro and in vivo. A, B. VSV-G pseudotyped Vif-deficient HIV-1 virions were harvested from
supernatants of 293T cells transfected with plasmids encoding Dvif-HIV-1(IIIB), VSV-G envelope and variable amounts of wt- and non-editing E259Q-
hA3G (Table 1). Total hA3G expression was examined using an antibody that binds to both wt- and E259Q-hA3G in immunoblots of both producer
cell lysates (1A) and purified virions (1B) at each titration; the transfection efficiency of both editing and non-editing hA3G was comparable. HIV-1 p24
protein was used as a loading control. C. Relative single-cycle infectivities of viruses from each titration were quantified by infecting TZM-bl cells that
express b-galactosidase under the control of an HIV-1 LTR with quantities of virus normalized by p24 ELISA. Infectivities were quantified using a b-
galactosidase reporter assay. The light signal gave a read-out of b-galactosidase production, which was proportional to the infectivity of the infecting
virus. Infectivities are expressed relative to that of VSV-G pseudotyped Dvif-HIV-1(IIIB) generated in the absence of any hA3G (condition 7). D. Using
single genome amplification, HIV-1 env-39LTR sequences were obtained from DNA isolated from cells infected with viruses from titration conditions
1–6. GG-to-AG (hA3G preferred dinucleotide) mutation rates were determined in each hypermutated virus from each condition relative to the known
parental virus sequence; non-hypermutated sequences are not included in this analysis; each data point represents the editing rate in one sequence;
for comparison with naturally occurring editing rates, GG-to-AG mutation rates were estimated in 39 patient-derived hypermutated sequences (‘‘in
vivo’’); dashed lines represent LM50/LM95/LM99 editing rates from the in silico simulations described in Figure 3. E. We used the proportions of
sequences carrying hA3G-type editing from each titration condition (Table 1 and Table 2) to generate a Maximum Likelihood Estimate of the number
of ‘‘positions’’ in a virion potentially occupied by wt-hA3G units; colours denote the data set omitted from the calculations in order to examine if all
titrations contributed equally to the estimation.
doi:10.1371/journal.pgen.1002550.g001
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codons were induced in 99% of simulations (LM99).
These estimates are highly conservative as they ignore the likely
harmful effects of most non-synonymous (NS, amino acid
changing) mutations and possible negative effects of synonymous
(S) changes on RNA secondary structure [36–38]. Both NS and S
mutations are more frequent than stop codons (e.g. at the nGGn-
to-nAGn LM50 rate, .80% of the simulations also had at least
one NS mutation (Figure 4C), and about 60% had multiple). At
these rates, only a few hA3G-induced mutations are needed to
inactivate progeny viruses and considering the hypermutation
rates observed in vitro, we found that the lowest hypermutation
frequency detected was ,10 fold higher than the estimated LM50
rate and over double the estimated LM99 rate (Figure 1D).
Collectively, our results suggest that even a single virion-
incorporated hA3G-unit rarely, if ever, generate G-to-A mutations
at sub-lethal levels but is very likely to cause extensive and
inactivating levels of HIV hypermutation.
Discussion
Here we investigate the pivotal question of whether hA3G-
induced G-to-A mutation is always lethal to the virus or if it may
occur at sub-lethal frequencies.
We examined whether limiting-levels of hA3G activity could
result in sub-lethal mutation rates using an in vitro hA3G titration
and sequencing experiment. The resulting in vitro mutation
patterns and per replication cycle rates were similar to mutation
levels found in in vivo hypermutated HIV DNA sequences implying
that our experimental data reflected natural infection [20].
Second, based on the proportions of sequences carrying
hypermutation in these datasets, we estimated that the maximum
number of editing hA3G molecules packaged in a virion was 13
(95% CI, 6–26), which was only slightly higher than a previous
biochemical estimate of 7+/24 molecules [28]. Using our
estimate, we calculated that it was highly likely that the
hypermutants we observed at the lowest wt-hA3G concentrations
in the titration experiments (Table 1) were caused by the
incorporation of just a single hA3G-unit, and this becomes even
more likely if the lower biochemical estimate is correct. As the
editing observed was extensive and induced inactivating levels of
G-to-A mutations, hypermutation typically seems to be an ‘‘all or
nothing’’ phenomenon.
It has been hypothesized that a proportion of hypermutated
sequences might be degraded by the cellular uracil DNA
glycosylases UNG2 and/or SMUG1 and that this may contribute
to the antiviral effect of hA3G [39,40]. This hypothesis is however
controversial [3] as few studies support it [41] while several have
demonstrated that the absence or inhibition of UNG2 and/or
SMUG1 activity neither abrogates hA3G inhibition of infection
nor rescues viral cDNA accumulation in infected cells, suggesting
that these enzymes are not involved in hA3G restriction of viral
replication [3,29–31]. Without conclusive data demonstrating
UNG-mediated degradation, it is impossible to model in a realistic
manner. However, we estimate that UNG-mediated degradation,
if it destroyed a large proportion of the hypermutated sequences,
would increase our estimation of k (the number of hA3G units in a
virion). This would however not impact on our analyses of the role
of hA3G in viral evolution in vivo as sequences that are degraded
disappear and do not form part of the viral population.
Third, we simulated editing in silico taking viral reading frames
into account, to determine how low levels of hA3G-induced G-to-
A mutations should be to increase viral diversification through
neutral or potentially beneficial mutations while avoiding
induction of lethal mutations (i.e. stop codons). We found that
due to hA3G tetranucleotide target preferences, which render it
efficient at generating stop codons, only a few mutations were
generally needed to inactivate progeny viruses. When we
compared the estimated LM50 rate with in vitro hypermutation
rates, we found that it was ,10 fold less than the very lowest
hypermutation frequency, suggesting that even a single hA3G-unit
rarely, if ever, causes G-to-A mutations at potentially beneficial
low levels.
Examining the role of hA3G in HIV evolution is an area of
active research. In vitro studies have used reporter-genes to
extrapolate the effect hA3G editing on HIV diversification [42]
and the nucleoside analog RT inhibitor 29,39-dideoxy-39-thia-
cytidine (3TC or Lamivudine) to assess the effect of hA3G on the
appearance of drug resistance mutations in lab-adapted HIV [43].
Population sequencing, which only detects polymorphisms present
in .20–25% of the viral population [44–47], was used to identify
drug-resistance mutations and as Lamivudine accumulates to
different degrees in different cell lines [48–51] and increases
intracellular dATP levels [52], which may affect RT misincor-
poration [13], the relevance of these studies for HIV evolution in
natural infection needs further examination.
Studies of patient-derived HIV sequences either directly support
ourfindingthathA3Gisunlikelytocontributetoviraldiversification
[13,53] or does not contrast it [54,55]. One report found that about
25% of rapidly diversifying sites inHIV were insequencemotifs that
could be mutated by either hA3C, hA3F, hA3G or RT [54].
Another study indicated that RT misincorporation was affected by
Table 2. Transfection condition and hypermutation results.
Transfection condition
r, Proportion of wt-
hA3G in transfection
h, Number of
hypermutated
sequences
n, Total number
of sequences
% sequences
hypermutated
% wild-type hA3G % E259Q-hA3G
1 0 100 0 0 7 0.0
2 1 99 0.01 2 19 10.5
3 3.3 96.7 0.033 9 19 47.4
4 10 90 0.1 15 19 78.9
5 33 67 0.33 14 15 93.3
6 1 0 0 0 1 881 0 0 . 0
7 0 0 0 ---
doi:10.1371/journal.pgen.1002550.t002
APOBEC3G, Hypermutation, and HIV Evolution
PLoS Genetics | www.plosgenetics.org 5 March 2012 | Volume 8 | Issue 3 | e1002550Figure 2. Probabilities of incorporation of editing wild-type hA3G units into progeny virions in the hA3G titration experiment. The
sensitivity of the MLE analysis in Figure 1E to each individual condition was assessed by re-estimating k after removing each state in turn. The values
of ri, ni, and hi are shown in Table 2. In each case, k refers to the hypothetical number of positions within a virion that could be occupied by wt-hA3G
units that can induce hypermutation; r denotes the proportion of wt-hA3G in the titration experiment (the proportion of non-editing E259Q-mutant
hA3G is 12r). Probabilities for each of the values of k spanning the 95% C.I. of the maximum likelihood estimate of the number of wt-hA3G units are
shown (MLE=13; 95% C.I.=6–26), and are based on the binomial distribution. (A–D) Probabilities of virions incorporating (A) zero wt-hA3G units, (B)
at least one wt-hA3G unit, (C) exactly one wt-hA3G unit, (D) two or more wt-hA3G units, for each model are shown. (E–F) graphs depicting the
probability of hypermutation having been caused by (E) a single wt-hA3G unit, or (F) more than one wt-hA3G unit.
doi:10.1371/journal.pgen.1002550.g002
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G-to-A mutations in HIV evolution, and found no sign of hA3F/G
editing [13]. A third study of plasma virus sequences from HIV-1
infected patients that were either drug-naı ¨ve or had failed HAART
demonstrated that Vif was highly polymorphic in both groups, but
more so in pretreated patients [55]. One of the Vif substitutions
(K22H) was further analyzed as another substitution (K22E) had
previously been demonstrated to partially neutralize hA3F but not
hA3G [4]. K22H was shown to partially neutralize hA3G whilst the
effect on hA3F was not tested. In vitro culture of mutated virus in
MT2 cells that express high levels of hA3F and hA3G [56] resulted
in a minority of the sequences carrying sub-lethal mutations, which
could be caused by either hA3F or hA3G. In contrast to hA3G,
hA3C and hA3F are likely to sometimes induce sub-lethal G-to-A
mutations as hA3F neutralization is dispensable for spread of HIV-1
in primary lymphocytes [56] and hA3C neutralization is not needed
for viral spread in SupT1 cells, which does not express hA3F and
hA3G [57]. A fourth cross-sectional study of patient-derived
sequences found no evidence of an evolutionary footprint of
hA3F/G [53] and studies of thousands of patient-derived sequences
have found either no, or very few, hypermutated RNA sequences,
suggesting that low-level hypermutation, or recombination between
hypermutated and non-hypermutated viruses, very rarely occurs in
vivo [12,23]. Such a recombination has been found only once in vitro
after co-transfection of 32 hypermutated and non-hypermutated
proviruses and 3TC drug selection [58].
As hA3G activity has such detrimental effects on HIV, strong
viral selective pressures must act to optimize Vif’s interaction with
hA3G. However, as variable levels of hypermutation are observed
in many HIV infected patients, other selective pressures may
sometimes also affect vif evolution. Several studies have demon-
strated that CD8+ cytotoxic T-cells (CTL) can target Vif [59–65]
and we hypothesize that these CTL responses sometimes select for
Vif variants that by chance interact less efficiently with hA3G. As
hypermutation frequency has been found to correlate inversely with
plasma viremia in three large patient cohorts [66–68], but not in
two smaller cohorts [69,70], increasing hypermutation frequencies
in patients through therapeutic measures is potentially beneficial.
Figure 3. Hypermutation is induced throughout HIV-1 genomes mutated by one wt-hA3G unit. We generated near-full length sequences
(gag to 39LTR) of a subset of hypermutated viruses from the lower wt-hA3G titrations (1% wt-hA3G:99% E259Q-hA3G (2a29) or 3.3% wt-hA3G: 96.7%
E259Q-hA3G (3a14, 3a16, 3a38, 3a78)) and determined the induced mutations by comparing the sequences with the known parental virus sequence.
Hypermutation profiles were made by calculating the number of GG and GA dinucleotides mutated to AG and AA, respectively, in 400bp sliding
windows to the 39 of the base under consideration. The positions of the central polypurine tract (cPPT) and 39PPT are indicated; the overall GG-to-AG
and GA-to-AA mutation rates in each sequence are indicated in the inset boxes. Colored rectangles indicate gaps in sequences.
doi:10.1371/journal.pgen.1002550.g003
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to increase HIV evolution and that hA3G-activity is highly likely
to inactivate HIV-1.
Materials and Methods
Plasmids, cell lines, and preparation of viral stocks
pcDNA3.1 expression vectors with wild-type hA3G (wt-A3G) or
non-editing E259Q mutant hA3G (E259Q-hA3G), VSV-G and the
vif-deficient HIV-1(IIIB) (pIIIB/Dvif) proviral construct have been
described previously [21,25,71–73]. Vif-deficiency was caused by the
introduction of two nonsense mutations while all other accessory
genes were functional. pIIIB/Dvif was furthermore modified with a
G-to-A mutation at position 571 of the 59LTR U5 region, which
copies to the 39LTR during reverse transcription, enabling
discrimination of viral sequences that have passed through a
replication cycle from those derived from the residual transfection
cocktail. VSV-G pseudotyped Dvif-HIV-1 was produced by
transfection of subconfluent monolayers of 293T cells using
polyethylenimine (PEI) (Polyscience). as in [25]. The transfection
efficiency of PEI is reported to be over 98% [74] and the average
number of transfected plasmids per cell using similar plasmid
concentrations and cell numbers is about 10
5 plasmid molecules [75].
The pIIIB/Dvif construct, VSV-G, and varied ratios of wt-hA3G to
E259Q-mutant hA3G were used (summarized in Table 1). Media
were changed after 6 h and supernatants were harvested after 24 hr
(hA3G titration experiment) or 48 hr (patient-derived Vif experi-
ment); virus production was quantified by p24 Gag ELISA (Perkin
Elmer),priortostorageat280uC and use in subsequent experiments.
Immunoblot analysis
For preparation of purified HIV-1 virion associated proteins,
virus supernatant equivalent to 30 ng of p24 Gag was diluted in
Figure 4. In silico simulation of hA3G-induced mutation in HIV(IIIB) open reading frames. A. Proposed relationship between viral fitness
benefit and cost and hA3G mutation rate modified from [3]. When hA3G edits HIV-1 genomes above a particular editing rate, the mutational burden
will be too high for the virus and a fitness cost is incurred, depicted in red. However, within a hypothetical window of hA3G activity, marked by the
blue line, the extent of editing induced might be low enough for the virus to survive. The additional mutations may help the virus adapt faster in a
fluctuating host environment and thus may be considered a viral fittness benefit. B. Each curve represents 100,000 in silico simulations of hA3G-
induced mutation of the HIV(IIIB) open reading frames (the virus used in all in vitro experiments) at 100 incremental mutation rates, at which the
proportion of sequences escaping in-frame stop codons was assessed. The number of mutations on the x-axis corresponds to the product of the
mutation rate and the total number of available targets. Simulations using three different nucleotide targets were performed; (i) G-to-A mutation (n
targets=1362), (ii) GG-to-AG mutation (n targets=667), and (iii) nGGn-to-nAGn mutation (n targets=662, with 16 specific nGGn mutation rates from
[20]). G-to-A simulations assumed that hA3G would recognized all Gn dinucleotide targets equally, GG-to-AG considered hA3G’s preferred di-
nucleotide target, while nGGn-to-nAGn simulations considered the 16 previously defined hA3G mutation rates [20] and thus more accurately
mirrored the specificity with which hA3G induces mutations in vivo. The number of mutations necessary to induce a stop codon in 50% of viral
offspring (LM50) decreased as the accuracy of the hA3G target increased from a single G to a di-nucleotide motif and lastly to a tetra-nucleotide
motif. LM50 mutation rates are shown and 95% confidence intervals (CI) are smaller than the data points. C. As in B however here the proportion of
simulations without non-synonomous substitutions and the associated LM50 was determined using the defined nGGn-to-nAGn mutation preferences
[20].
doi:10.1371/journal.pgen.1002550.g004
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centrifuged for 2 hours at 14000 rpm at 4Cu and supernatants
removed. Purified virions or infected 293T cells were lysed,
centrifuged to remove cell debris, and prepared for loading onto
SDS-PAGE gels in a 1:1:1 mix of 36SDS-PAGE sample buffer
(180 mM Tris, pH 6.8; 9% (w/v) SDS; 30% glycerol; bromophe-
nol blue), DTT (in PBS, giving a final concentration of 100 mM)
and lysate, and were incubated for 10 minutes at 95uC. 5–10 mlo f
samples were loaded into a 4% stacking gel on a 12% separating
gel and run for 1 hr at 25 mA/gel at maximum voltage. Proteins
were transferred from gels onto PVDF membranes (pre-soaked in
methanol and running buffer (WB: 0.1% Tween20 in PBS)) at
16 V overnight; membranes were blocked in 5% milk powder in
WB for at least 30 minutes, prior to incubation with primary
antibody (either anti-hA3G (recognizing both wt- and E259Q-
hA3G) or anti-p24
CA (loading control) diluted in 5% milk powder/
WB) for 1 hr at room temperature. After rinsing 3 times and
washing 4 times for 59 with WB, membranes were incubated with
horseradish-peroxidase conjugated secondary antibody (diluted in
5% milk powder/WB) for 409 at room temperature, and the rinse/
wash procedure was repeated. Membranes were then incubated
for 1–59 with ECL substrate before exposure to film as in [25].
Viral infections, single-cycle infectivity, and DNA
purification
TZM-bl cells (a HeLa cell line expressing HIV-1 co-receptors
and a lacZ reporter gene under control of an HIV-1 LTR
promoter) were infected with 293T cell produced VSV-G-
pseudotyped Dvif-HIV-1 virions containing various ratios of wt-
hA3G to E259Q-mutant hA3G (hA3G titration experiment) or
Dvif-HIV-1 virions containing hA3G and patient derived Vif
(patient-derived Vif experiment). After 24 hrs, supernatants were
removed and cells were washed with PBS, before lysing with
200 ml lysis solution. Following transfer to microfuge tubes, debris
from cell lysates was pelleted by microcentrifugation at
14,000 rpm for 10 minutes and 20 mlc e l le x t r a c tw a st h e na d d e d
to 100 ml Galacton-Star (reporter gene assay system for
mammalian cells) substrate (Applied Biosystems Inc., CA, USA)
diluted 1:50 with reaction buffer diluent in white microplate
wells. The light signal was measured every 10–15 minutes up to
2 hr after the start of the reaction on a luminometer, giving a
read-out of b-galactosidase production, which is proportional to
the infectivity of the infecting virus. For sequencing experiments,
total DNA was extracted from infected cells using the DNeasy
DNA extraction kit (Qiagen Inc, CA, USA) and digested with
DpnI (New England Biolabs), a restriction endonuclease that
specifically targets methylated DNA, to remove carried-over
transfection mixture.
Amplification of near-full length proviral genomes
Near-full length proviral single genomes were amplified by
limiting dilution nested PCR using Advantage 2 Polymerase mix
(TakaraBio/Clontech, Paris, France) and HIV-1 specific oligonu-
cleotide primers, as described previously [20]. The product of an
8.5 kb first-round PCR from gag-to-39LTR was used as a template
for a second-round PCR spanning env-to-39LTR (2.1 kb, 8–20
fragments per hA3G transfection condition, 87 amplicons in
total)(Figure S2). For a subset of sequences, gag-to-pol, pol-to-vif,
and vif-to-env fragments were amplified to derive near-full length
sequences. Where possible, primers (Table S2) were designed to
exclude 59GG or 59GA (plus-strand) or 59CC or 59TC (minus-
strand) motifs, the preferred contexts for hA3F and hA3G activity
respectively, in order to reduce the potential for bias in
amplification of hypermutated viruses. Amplicons were purified
using the QIAquick PCR purification kit (Qiagen Incorporated,
CA, USA) and both strands were sequenced directly using
Dyedeoxy Terminator sequencing (Applied Biosystems, CA,
USA) on an Applied Biosystems 3730xl DNA Analyzer as
previously described [20]. DNA reads were assembled and
proofread using the Pregap4 and Gap4 software within the
Staden package [76] (Figure S2). Sequences lacking the engineered
G-to-A mutation in the 39LTR [72] were assumed to be carried-
over transfection mixture and were discarded. Sequences were
screened for evidence of hA3G-mediated editing/hypermutation
(defined as a mutational process in which G-to-A transitions far
exceed all other mutations [19]) using the HYPERMUT software
(www.hiv.lanl.gov) [77].
MLE of the number of virion-associated hA3G-units
The proportion of sequences carrying evidence of hypermuta-
tion at each titration was used to generate a MLE of the average
number of deaminating hA3G units incorporated into a progeny
virion. Our analysis assumes (i) that there are a limited number of
positions in a virion that can be occupied by hA3G-editing units
[28]. The number of such positions, denoted k, is unknown, but we
can use our titrations to obtain a maximum likelihood estimate of
its value. Let us denote as ri, the proportion of the hA3G in
transfection condition i that is wild-type editing (wt-hA3G), as
opposed to non-editing (E259Q-hA3G); for example, from Table 1
and Table 2, in condition 5, r5=0.33. How likely is a virion to
incorporate an editing hA3G-unit under this condition? To answer
this question, we assume (ii) that the efficiency of transfection,
protein expression, and virion incorporation is the same for editing
and non-editing hA3G; and (iii) that there is sufficient hA3G
present in each titration for all k slots to be occupied. Under these
three assumptions, the probability that a virion incorporates one
or more editing hA3G-units is simply qi=12(12ri)
k. If we further
assume (iv) that detectable hypermutation always ensues from the
incorporation of one or more editing hA3G-units, then qi is also
the probability that a sequence undergoes hypermutation. As such,
given a sample of ni sequences, the probability that hi of them
will be hypermutants is the binomial probability:P(hi)~
qi
hi(1{qi)
ni{hi hi
ni

. Because qi is a function of k we can now
write the likelihood function of k as L(k)~ P
titrations
i
Ph i ðÞ , and
thereby obtain the value of k that is most likely to have given rise to
our data, i.e., the value that maximises L(k). 95% confidence
intervals on this estimate were obtained by assuming that twice the
log likelihood ratio is x
2 -distributed with 1 degree of freedom, and
the sensitivity of the analysis to each individual condition was
assessed by jackknifing, i.e., reestimating k after removing each
condition in turn. Results of the analyses are shown in Figure 1E
and Figure 2, and the values of ri, ni, and hi are shown in Table 2.
The approximation for the probability that an observed
hypermutated sequence has arisen from the incorporation of a
single hA3G-editing unit is obtained from:
kri(1{ri)
k{1
1{(1{ri)
k &1{
1
2
(k{1)rizO(r2
i )
Analyses of in vivo hypermutated HIV DNA
The thirty-eight near-full length HIV genomes annotated as
hypermutated in the Los Alamos HIV sequence database (www.
hiv.lanl.gov) at the time of this analysis and one non-annotated
hypermutated sequence (EF036536) were used to estimate levels of
APOBEC3G, Hypermutation, and HIV Evolution
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by examining GenBank entries of 1725 near-full length HIV
genomes. The sequences were tested by the search terms ‘stop’,
‘truncated’, ‘truncation’, ‘terminated’, ‘termination’, ‘mutated’,
‘mutation’, ‘hypermutated’, ‘hypermutation’, ‘non-functional’, and
‘nonfunctional’, and those carrying more than 4 stop codons were
tested for evidence of hA3G-induced mutations as previously
described [20]; analyses of sequences with fewer mutations was not
possible due to noise. GG-to-AG mutation rates were estimated for
each of these 39 hypermutated sequences using reference
sequences generated from closely related taxa identified by NJ
phylogenetic tree analyses as described previously [20]. GG-to-AG
mutation rates were corrected for probable non-hA3G-mediated
mutation by subtracting the mean of the GC-to-AC and GT-to-
AT mutation rates in each sample from the GG-to-AG mutation
rate, after adjusting for the biased nucleotide composition of the
HIV genome in each case (GC and GT are seldom mutated by
hA3G in single cycle in vitro infections [20].
In silico simulations
The open reading frames of HIV-1 pIIIB, (the virus used in the
in vitro analyses) were used in computer simulations of hA3G-
induced mutation (Figure S1). Predefined nGGn-to-nAGn muta-
tion rates and the array of defined hA3G nGGn-to-nAGn
mutation preferences [20] were used to determine the probability
of mutation of each nGGn context. The mutation rate required to
induce at least one stop codon in open reading frames in 50% of
the simulations (the Lethal Mutation 50% or LM50) was
determined from 100,000 simulations of 100 incremental mutation
rates in simulations of G-to-A, GG-to-AG and nGGn-to-nGAn
mutations. Other thresholds such as LM95 and LM99 were also
determined. The proportion of simulations without non-synono-
mous substitutions and the LM50 was also determined using the
defined nGGn-to-nAGn mutation preferences [20].
The simulations did not account for the proposed twin gradient
hypothesis for hypermutation, whereby the hA3G-induced
mutational burden across individual genomes is proposed to
increase from minima at the polypurine tracts (PPTs) in a plus-
strand 59-39 direction [17,33] as existing data are insufficient to
model this effect [20,78]. Nevertheless, since the twin gradient
hypothesis predicts higher levels of mutation in the structural pol
and env genes (most distal to the 39 ends of the PPTs), we predict
that at a given mutation rate, simulations modeling this effect
would yield increased numbers of stop codons in these genes with
respect to the simulations described; thus our estimates are
conservative.
Supporting Information
Figure S1 The HIVIIIB sequence (similar to the one used in the
in vitro experiments) in alignment with ORFs as used in the
simulations.
(PDF)
Figure S2 HIVIIIB sequence alignments from the in vitro
titration experiment: 1) envLTR and 2) almost full-length provirus.
(PDF)
Table S1 Mutation summary.
(PDF)
Table S2 PCR primers.
(PDF)
Table S3 GenBank accession numbers.
(PDF)
Acknowledgments
We thank Michael Malim for reagents and helpful discussions and the
Computational Biology Research Group, Oxford, for access to sequence
analyses software.
Author Contributions
Conceived and designed the experiments: AKNI AEA AR. Performed the
experiments: AEA C-hC EW BK AKNI. Analyzed the data: AKNI AEA
KD JJW AR. Contributed reagents/materials/analysis tools: KD AR
AKNI JG LF AJM. Wrote the paper: AKNI. Provided intellectual input
during the writing of the manuscript: AEA KD JJW AR. Commented on
the final version of the manuscript: AEA KD C-hC EW BK JJW JG LF
AM AR AKNI.
References
1. Rambaut A, Posada D, Crandall KA, Holmes EC (2004) The causes and
consequences of HIV evolution. Nat Rev Genet 5: 52–61.
2. Hache G, Mansky LM, Harris RS (2006) Human APOBEC3 proteins,
retrovirus restriction, and HIV drug resistance. AIDS Rev 8: 148–57.
3. Malim MH (2009) APOBEC proteins and intrinsic resistance to HIV-1
infection. Philos Trans R Soc Lond B Biol Sci 364: 675–87.
4. Simon V, Zennou V, Murray D, Huang Y, Ho DD, et al. (2005) Natural
variation in Vif: differential impact on APOBEC3G/3F and a potential role in
HIV-1 diversification. PLoS Pathog 1: e6. doi:10.1371/journal.ppat.0010006.
5. Zhang H, Yang B, Pomerantz RJ, Zhang C, Arunachalam SC, et al. (2003) The
cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1
DNA. Nature 424: 94–8.
6. Harris RS (2008) Enhancing immunity to HIV through APOBEC. Nat
Biotechnol 26: 1089–90.
7. Malim MH (2006) Natural resistance to HIV infection: The Vif-APOBEC
interaction. C R Biol 329: 871–5.
8. Kypr J, Mrazek J (1987) Unusual codon usage of HIV. Nature 327(6117): 20.
9. Berkhout B, van Hemert FJ (1994) The unusual nucleotide content of the HIV
RNA genome results in a biased amino acid composition of HIV proteins.
Nucleic Acids Res 22: 1705–11.
10. Berkhout B, de Ronde A (2004) APOBEC3G versus reverse transcriptase in the
generation of HIV-1 drug-resistance mutations. Aids 18: 1861–3.
11. Gao F, Chen Y, Levy DN, Conway JA, Kepler TB, et al. (2004) Unselected
mutations in the human immunodeficiency virus type 1 genome are mostly
nonsynonymous and often deleterious. J Virol 78: 2426–33.
12. Keele BF, Giorgi EE, Salazar-Gonzalez JF, Decker JM, Pham KT, et al.
(2008) Identification and characterization of transmitted and early founder
virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci U S A 105:
7552–7.
13. Deforche K, Camacho R, Laethem KV, Shapiro B, Moreau Y, et al. (2007)
Estimating the Relative Contribution of dNTP Pool Imbalance and APO-
BEC3G/3F Editing to HIV Evolution In Vivo. J Comput Biol 14: 1105–14.
14. Soros VB, Yonemoto W, Greene WC (2007) Newly synthesized APOBEC3G is
incorporated into HIV virions, inhibited by HIV RNA, and subsequently
activated by RNase H. PLoS Pathog 3: e15. doi:10.1371/journal.ppat.0030015.
15. Mangeat B, Turelli P, Caron G, Friedli M, Perrin L, et al. (2003) Broad
antiretroviral defence by human APOBEC3G through lethal editing of nascent
reverse transcripts. Nature 424: 99–103.
16. Bishop KN, Verma M, Kim EY, Wolinsky SM, Malim MH (2008) APOBEC3G
inhibits elongation of HIV-1 reverse transcripts. PLoS Pathog 4: e1000231.
doi:10.1371/journal.ppat.1000231.
17. Yu Q, Konig R, Pillai S, Chiles K, Kearney M, et al. (2004) Single-strand
specificity of APOBEC3G accounts for minus-strand deamination of the HIV
genome. Nat Struct Mol Biol 11: 435–42.
18. Suspene R, Sommer P, Henry M, Ferris S, Guetard D, et al. (2004)
APOBEC3G is a single-stranded DNA cytidine deaminase and functions
independently of HIV reverse transcriptase. Nucleic Acids Res 32: 2421–9.
19. Vartanian JP, Meyerhans A, Sala M, Wain-Hobson S (1994) GRA
hypermutation of the human immunodeficiency virus type 1 genome: evidence
for dCTP pool imbalance during reverse transcription. Proc Natl Acad Sci U S A
91: 3092–6.
20. Armitage AE, Katzourakis A, de Oliveira T, Welch JJ, Belshaw R, et al. (2008)
Conserved footprints of APOBEC3G on Hypermutated human immunodefi-
ciency virus type 1 and human endogenous retrovirus HERV-K(HML2)
sequences. J Virol 82: 8743–61.
21. Sheehy AM, Gaddis NC, Malim MH (2003) The antiretroviral enzyme
APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nat Med
9(11): 1404–7.
APOBEC3G, Hypermutation, and HIV Evolution
PLoS Genetics | www.plosgenetics.org 10 March 2012 | Volume 8 | Issue 3 | e100255022. Gandhi SK, Siliciano JD, Bailey JR, Siliciano RF, Blankson JN (2007) The role
of APOBEC3G/F-mediated hypermutation in the control of HIV-1 in Elite
Suppressors. J Virol 82: 3125–30.
23. Kieffer TL, Kwon P, Nettles RE, Han Y, Ray SC, et al. (2005) GRA
hypermutation in protease and reverse transcriptase regions of human
immunodeficiency virus type 1 residing in resting CD4+ T cells in vivo. J Virol
79: 1975–80.
24. Janini M, Rogers M, Birx DR, McCutchan FE (2001) Human immunodefi-
ciency virus type 1 DNA sequences genetically damaged by hypermutation are
often abundant in patient peripheral blood mononuclear cells and may be
generated during near-simultaneous infection and activation of CD4(+) T cells.
J Virol 75: 7973–86.
25. Newman EN, Holmes RK, Craig HM, Klein KC, Lingappa JR, et al. (2005)
Antiviral function of APOBEC3G can be dissociated from cytidine deaminase
activity. Curr Biol 15: 166–70.
26. Holmes RK, Koning FA, Bishop KN, Malim MH (2007) APOBEC3F can
inhibit the accumulation of HIV-1 reverse transcription products in the absence
of hypermutation. Comparisons with APOBEC3G. J Biol Chem 282: 2587–95.
27. Huthoff H, Autore F, Gallois-Montbrun S, Fraternali F, Malim MH (2009)
RNA-dependent oligomerization of APOBEC3G is required for restriction of
HIV-1. PLoS Pathog 5: e1000330. doi:10.1371/journal.ppat.1000330.
28. Xu H, Chertova E, Chen J, Ott DE, Roser JD, et al. (2006) Stoichiometry of the
antiviral protein APOBEC3G in HIV-1 virions. Virology 360: 247–56.
29. Kaiser SM, Emerman M (2006) Uracil DNA glycosylase is dispensable for
human immunodeficiency virus type 1 replication and does not contribute to the
antiviral effects of the cytidine deaminase Apobec3G. J Virol 80: 875–82.
30. Mbisa JL, Barr R, Thomas JA, Vandegraaff N, Dorweiler IJ, et al. (2007)
Human immunodeficiency virus type 1 cDNAs produced in the presence of
APOBEC3G exhibit defects in plus-strand DNA transfer and integration. J Virol
81: 7099–110.
31. Langlois MA, Neuberger MS (2008) Human APOBEC3G can restrict retroviral
infection in avian cells and acts independently of both UNG and SMUG1.
J Virol 82: 4660–4.
32. Wurtzer S, Goubard A, Mammano F, Saragosti S, Lecossier D, et al. (2006)
Functional central polypurine tract provides downstream protection of the
human immunodeficiency virus type 1 genome from editing by APOBEC3G
and APOBEC3B. J Virol 80: 3679–83.
33. Suspene R, Rusniok C, Vartanian JP, Wain-Hobson S (2006) Twin gradients in
APOBEC3 edited HIV-1 DNA reflect the dynamics of lentiviral replication.
Nucleic Acids Res 34: 4677–84.
34. Jern P, Russell RA, Pathak VK, Coffin JM (2009) Likely role of APOBEC3G-
mediated G-to-A mutations in HIV-1 evolution and drug resistance. PLoS
Pathog. e1000367 p. doi:10.1371/journal.ppat.1000367.
35. Furukawa A, Nagata T, Matsugami A, Habu Y, Sugiyama R, et al. (2009)
Structure, interaction and real-time monitoring of the enzymatic reaction of
wild-type APOBEC3G. Embo J 28: 440–51.
36. Pybus OG, Rambaut A, Belshaw R, Freckleton RP, Drummond AJ, et al. (2007)
Phylogenetic evidence for deleterious mutation load in RNA viruses and its
contribution to viral evolution. Mol Biol Evol 24: 845–52.
37. Sanjuan R, Moya A, Elena SF (2004) The distribution of fitness effects caused by
single-nucleotide substitutions in an RNA virus. Proc Natl Acad Sci U S A 101:
8396–401.
38. Wang Q, Barr I, Guo F, Lee C (2008) Evidence of a novel RNA secondary
structure in the coding region of HIV-1 pol gene. Rna 14: 2478–88.
39. Harris RS, Bishop KN, Sheehy AM, Craig HM, Petersen-Mahrt SK, et al.
(2003) DNA deamination mediates innate immunity to retroviral infection. Cell
113: 803–9.
40. Harris RS, Sheehy AM, Craig HM, Malim MH, Neuberger MS (2003) DNA
deamination: not just a trigger for antibody diversification but also a mechanism
for defense against retroviruses. Nat Immunol 4: 641–3.
41. Yang B, Chen K, Zhang C, Huang S, Zhang H (2007) Virion-associated uracil
DNA glycosylase-2 and apurinic/apyrimidinic endonuclease are involved in the
degradation of APOBEC3G-edited nascent HIV-1 DNA. J Biol Chem 282:
11667–75.
42. Sadler HA, Stenglein MD, Harris RS, Mansky LM (2010) APOBEC3G
contributes to HIV-1 variation through sublethal mutagenesis. J Virol 84:
7396–404.
43. Kim EY, Bhattacharya T, Kunstman K, Swantek P, Koning FA, et al. (2010)
Human APOBEC3G-mediated editing can promote HIV-1 sequence diversi-
fication and accelerate adaptation to selective pressure. J Virol 84: 10402–5.
44. Kapoor A, Jones M, Shafer RW, Rhee SY, Kazanjian P, et al. (2004)
Sequencing-based detection of low-frequency human immunodeficiency virus
type 1 drug-resistant mutants by an RNA/DNA heteroduplex generator-
tracking assay. J Virol 78: 7112–23.
45. Hauser A, Mugenyi K, Kabasinguzi R, Kuecherer C, Harms G, et al. (2011)
Emergence and persistence of minor drug-resistant HIV-1 variants in Ugandan
women after nevirapine single-dose prophylaxis. PLoS ONE 6: e20357.
doi:10.1371/journal.pone.0020357.
46. Svarovskaia ES, Moser MJ, Bae AS, Prudent JR, Miller MD, et al. (2006)
MultiCode-RTx real-time PCR system for detection of subpopulations of K65R
human immunodeficiency virus type 1 reverse transcriptase mutant viruses in
clinical samples. J Clin Microbiol 44: 4237–41.
47. D’Aquila RT, Geretti AM, Horton JH, Rouse E, Kheshti A, et al. (2011)
Tenofovir (TDF)-selected or abacavir (ABC)-selected low-frequency HIV type 1
subpopulations during failure with persistent viremia as detected by ultradeep
pyrosequencing. AIDS Res Hum Retroviruses 27: 201–9.
48. Hazen R, Lanier ER (2003) Relative anti-HIV-1 efficacy of lamivudine and
emtricitabine in vitro is dependent on cell type. J Acquir Immune Defic Syndr
32: 255–8.
49. Turriziani O, Schuetz JD, Focher F, Scagnolari C, Sampath J, et al. (2002)
Impaired 29,39-dideoxy-39-thiacytidine accumulation in T-lymphoblastoid cells
as a mechanism of acquired resistance independent of multidrug resistant
protein 4 with a possible role for ATP-binding cassette C11. Biochem J 368:
325–32.
50. Schuetz JD, Connelly MC, Sun D, Paibir SG, Flynn PM, et al. (1999) MRP4: A
previously unidentified factor in resistance to nucleoside-based antiviral drugs.
Nat Med 5: 1048–51.
51. Wijnholds J, Mol CA, van Deemter L, de Haas M, Scheffer GL, et al. (2000)
Multidrug-resistance protein 5 is a multispecific organic anion transporter able
to transport nucleotide analogs. Proc Natl Acad Sci U S A 97: 7476–81.
52. Bantia S, Ananth SL, Parker CD, Horn LL, Upshaw R (2003) Mechanism of
inhibition of T-acute lymphoblastic leukemia cells by PNP inhibitor–BCX-1777.
Int Immunopharmacol 3: 879–87.
53. Ebrahimi D, Anwar F, Davenport MP (2011) APOBEC3 has not left an
evolutionary footprint on the HIV-1 genome. J Virol 85: 9139–46.
54. Wood N, Bhattacharya T, Keele BF, Giorgi E, Liu M, et al. (2009) HIV
evolution in early infection: selection pressures, patterns of insertion and
deletion, and the impact of APOBEC. PLoS Pathog 5: e1000414. doi:10.1371/
journal.ppat.1000414.
55. Fourati S, Malet I, Binka M, Boukobza S, Wirden M, et al. (2010) Partially
active HIV-1 Vif alleles facilitate viral escape from specific antiretrovirals. Aids
24: 2313–21.
56. Mulder LC, Ooms M, Majdak S, Smedresman J, Linscheid C, et al. (2010)
Moderate influence of human APOBEC3F on HIV-1 replication in primary
lymphocytes. J Virol 84: 9613–7.
57. Bourara K, Liegler TJ, Grant RM (2007) Target cell APOBEC3C can induce
limited G-to-A mutation in HIV-1. PLoS Pathog 3: e153. doi:10.1371/
journal.ppat.0030153.
58. Mulder LC, Harari A, Simon V (2008) Cytidine deamination induced HIV-1
drug resistance. Proc Natl Acad Sci U S A 105: 5501–6.
59. Rousseau CM, Daniels MG, Carlson JM, Kadie C, Crawford H, et al. (2008)
HLA class I-driven evolution of human immunodeficiency virus type 1 subtype c
proteome: immune escape and viral load. J Virol 82: 6434–46.
6 0 .C h e nJ ,H o n gK ,J i aM ,L i uH ,Z h a n gY ,e ta l .( 2 0 0 7 )H u m a n
immunodeficiency virus type 1 specific cytotoxic T lymphocyte responses in
Chinese infected with HIV-1 B’/C Recombinant (CRF07_BC). Retrovirology 4:
62.
61. Yu XG, Lichterfeld M, Addo MM, Altfeld M (2005) Regulatory and accessory
HIV-1 proteins: potential targets for HIV-1 vaccines? Curr Med Chem 12(6):
741–7.
62. Addo MM, Yu XG, Rosenberg ES, Walker BD, Altfeld M (2002) Cytotoxic T-
lymphocyte (CTL) responses directed against regulatory and accessory proteins
in HIV-1 infection. DNA Cell Biol 21: 671–8.
63. Novitsky V, Cao H, Rybak N, Gilbert P, McLane MF, et al. (2002) Magnitude
and frequency of cytotoxic T-lymphocyte responses: identification of immuno-
dominant regions of human immunodeficiency virus type 1 subtype C. J Virol
76: 10155–68.
64. Altfeld M, Addo MM, Eldridge RL, Yu XG, Thomas S, et al. (2001) Vpr is
preferentially targeted by CTL during HIV-1 infection. J Immunol 167:
2743–52.
65. Kiepiela P, Ngumbela K, Thobakgale C, Ramduth D, Honeyborne I, et al.
(2007) CD8+ T-cell responses to different HIV proteins have discordant
associations with viral load. Nat Med 13: 46–53.
66. Pace C, Keller J, Nolan D, James I, Gaudieri S, et al. (2006) Population level
analysis of human immunodeficiency virus type 1 hypermutation and its
relationship with APOBEC3G and vif genetic variation. J Virol 80: 9259–69.
67. Land AM, Ball TB, Luo M, Pilon R, Sandstrom P, et al. (2008) Human
immunodeficiency virus (HIV) type 1 proviral hypermutation correlates with
CD4 count in HIV-infected women from Kenya. J Virol 82: 8172–82.
68. Vazquez-Perez JA, Ormsby CE, Hernandez-Juan R, Torres KJ, Reyes-Teran G
(2009) APOBEC3G mRNA expression in exposed seronegative and early stage
HIV infected individuals decreases with removal of exposure and with disease
progression. Retrovirology 6: 23.
69. Ulenga NK, Sarr AD, Hamel D, Sankale JL, Mboup S, et al. (2008) The level of
APOBEC3G (hA3G)-related G-to-A mutations does not correlate with viral load
in HIV type 1-infected individuals. AIDS Res Hum Retroviruses 24: 1285–90.
70. Piantadosi A, Humes D, Chohan B, McClelland RS, Overbaugh J (2009)
Analysis of the percentage of human immunodeficiency virus type 1 sequences
that are hypermutated and markers of disease progression in a longitudinal
cohort, including one individual with a partially defective Vif. J Virol 83:
7805–14.
71. Simon JH, Southerling TE, Peterson JC, Meyer BE, Malim MH (1995)
Complementation of vif-defective human immunodeficiency virus type 1 by
primate, but not nonprimate, lentivirus vif genes. J Virol 69: 4166–72.
72. Bishop KN, Holmes RK, Sheehy AM, Davidson NO, Cho SJ, et al. (2004)
Cytidine deamination of retroviral DNA by diverse APOBEC proteins. Curr
Biol 2004. 14: 1392–6.
APOBEC3G, Hypermutation, and HIV Evolution
PLoS Genetics | www.plosgenetics.org 11 March 2012 | Volume 8 | Issue 3 | e100255073. Bishop KN, Holmes RK, Sheehy AM, Malim MH (2004) APOBEC-mediated
editing of viral RNA. 305: 645.
74. Reed SE, Staley EM, Mayginnes JP, Pintel DJ, Tullis GE (2006) Transfection of
mammalian cells using linear polyethylenimine is a simple and effective means of
producing recombinant adeno-associated virus vectors. J Virol Methods 138:
85–98.
75. Tseng WC, Haselton FR, Giorgio TD (1997) Transfection by cationic liposomes
using simultaneous single cell measurements of plasmid delivery and transgene
expression. J Biol Chem 272: 25641–7.
76. Staden R, Beal KF, Bonfield JK (2000) The Staden package Methods Mol Biol
132: 115–30.
77. Rose PP, Korber BT (2000) Detecting hypermutations in viral sequences with an
emphasis on GRA hypermutation. Bioinformatics 16: 400–1.
78. Kijak GH, Janini LM, Tovanabutra S, Sanders-Buell E, Arroyo MA (2008)
Variable contexts and levels of hypermutation in HIV-1 proviral genomes
recovered from primary peripheral blood mononuclear cells. Virology 376:
101–11.
APOBEC3G, Hypermutation, and HIV Evolution
PLoS Genetics | www.plosgenetics.org 12 March 2012 | Volume 8 | Issue 3 | e1002550